More than half of patients in pain management study took no opioids after operations

Patients reported postoperative pain was manageable, according to study by Michigan Medicine

Author | Kara Gavin

The opioid epidemic has become a public health crisis in the U.S. While primary care physicians have been writing fewer opioid prescriptions over the last several years, new opioid prescriptions by surgeons increased 18 percent from 2010-2016.

However, many surgeons are now diligently working to change their prescribing practices.

A collaborative effort led by surgeons at Michigan Medicine seeks to reduce excessive opioid prescriptions by exploring pain management strategies that include fewer or no opioids for surgical patients.

The latest approach: to find out if an opioid-sparing strategy would be feasible for patients undergoing six different procedures at their institution.

Results from their pilot study showed that more than half of patients used no opioids after their operations, and almost all of the patients reported their pain was manageable, according to study findings published online ahead of print in the Journal of the American College of Surgeons.

The study team, led by Michael Englesbe, M.D., FACS, a health services researcher at the U-M Institute for Healthcare Policy and Innovation, has been working to improve opioid prescribing in Michigan for two years.

Their work is motivated by the fact that many people who are not taking opioids before their operations (“opioid-naïve”) become new chronic opioid users after their operations, says Englesbe, the study’s corresponding author and a professor of surgery at the University of Michigan.

“We think a fundamental root cause of the opioid epidemic is opioid-naïve patients getting exposed to opioids and then really struggling to stop taking them postoperatively, and then moving on to chronic opioid use, abuse, addiction, and overdose,” Englesbe says.

For this study, the goal was to have a majority of patients need no opioid pills after their operations.

The researchers enrolled 190 opioid-naïve patients undergoing six surgical procedures at their institution: laparoscopic cholecystectomy, laparoscopic inguinal hernia repair, thyroidectomy/parathyroidectomy, robotic prostatectomy, endoscopic sinus operations, and laparoscopic sleeve gastrectomy.

Participants received specific instructions regarding postoperative pain control, pain expectations, and counseling to learn to manage pain without opioids.

At their preoperative clinic visits, patients were told to take acetaminophen or ibuprofen every six hours around the clock and to stagger these medications every three hours for maximum continuous pain control.

After their operations, patients received prescriptions for 650 mg of acetaminophen and 600 mg of ibuprofen, as well as a small “rescue” prescription of opioids for uncontrolled breakthrough pain.

The prescription sizes of opioids—mostly oxycodone—varied based on the operation but were small. For example, laparoscopic cholecystectomy patients were prescribed four oxycodone pills.

Patients were instructed during both their preoperative and postoperative clinic visits that they didn’t have to use the opioids if they didn’t feel they needed to.

During the first week after their operations, patients were asked to rate their average pain score on a scale of no pain (0) to severe pain (3). They were also asked to rate their surgical site pain at the time of the survey, their satisfaction with the operation, their quality of life after the operation, the percent recovered they felt at the time of the survey, and whether they regretted having the operation.

Patients also reported whether they used acetaminophen and/or ibuprofen, and whether their pain was manageable with this regimen. Between 30 and 90 days after their operations, patients were asked to report the number of opioid pills they used postoperatively.

The study authors reported that 52 percent of patients used no opioids after their operations, and 98 percent used 10 pills or fewer.

Among the 48 percent of patients who did use opioids, the median use was four pills, and the median number of leftover pills was two. The median pain score for the whole cohort was 1, or minimal pain; that number was 2 for patients who used opioids.

Overall, the median patient satisfaction score was 10 on a 10-point scale, or extremely satisfied, and the median quality of life score was 4 on a 5-point scale. The median level of regret to undergo the operation was 5 (“absolutely no regret”). There were no significant differences in the other variables when comparing opioid users with non-users, the authors reported.

Almost all patients—91 percent—said their pain was manageable using this strategy.

While Englesbe said it was a bit surprising—and very motivating—that a significant percentage of patients took no opioids, it’s also important to understand that fewer opioids are only one component of the larger pain management strategy. The focus has to be on what does work, which will not be the same for every patient.

“Just not giving opioids is not the answer—we have to give the best pain care,” Englesbe says. In the case of this study, the team provided a full care pathway.

“From the beginning, everyone was on the same page with talking to patients about their pain and letting them know that operations hurt,” he adds.

With the help of funding from Blue Cross Blue Shield of Michigan and the Michigan Department of Health and Human Services, Englesbe and his team are in the process of expanding this pain management strategy.

They will expand their list of selected surgical procedures from six to 18 and are working to implement the strategy to other institutions across the state.

“Our overall goal is to have half the operations done in the state of Michigan without patients needing opioids and still getting excellent pain care,” Englesbe says. “There are alternatives to opioids for surgical pain that work well and we should be using them more.”

Additional authors include Alexander Hallway, BS; Joceline Vu, MD; Jay Lee, MD; William Palazzolo, PA-C; Jennifer Waljee, MD, MS, MPH; Chad Brummett, MD; and Ryan Howard, MD, of Michigan Medicine.

 

News release courtesy American College of Surgeons.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Featured News & Stories The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
Cannabis and psychedelics: stigmatized substances or powerful therapeutics?
Today on The Fundamentals is Dr. Kevin Boehnke, research assistant professor in the Department of Anesthesiology and the Chronic Pain and Fatigue Research Center. His current research focuses on therapeutic applications of cannabis and psychedelics. His goal is to rigorously assess appropriate use of these substances and to help address the public health harms caused by their criminalization.
Health Lab
Mother-son heart bond: Woman relives congenital heart journey through newborn
A mother relives congenital heart journey through newborn.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
Treating Diabetes & Weight: The Ozempic & Wegovy Effect
Today on The Fundamentals, our guest Dr. Martin Myers, Director of the U-M Elizabeth Weiser Caswell Diabetes Institute, discusses diabetes research in the context of Ozempic, Wegovy, and other drugs that are changing how people think about weight loss. You can learn more about Dr. Myers here, and you can follow the department of molecular and integrative physiology @UMPhysiology on X.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
If they don't give up, how can I give up?
Today on The Fundamentals is Dr. Maria Castro, the R.C. Schneider collegiate professor of neurosurgery, and a professor of cell and developmental biology at the University of Michigan Medical School. Her research program aims to develop immunotherapies for primary and metastatic brain cancer, studying basic immune biology mechanisms leading to clinical implementation. She has been inducted into the American Association for the Advancement of Sciences, the Latin American Academy of Sciences, and the American Institute for Medical and Biological Engineering College of Fellows. She has won numerous awards for her contributions to basic science and cancer research and is a diversity ambassador for the Cancer Biology Graduate Training Program. You can learn more about Dr. Castro here, and you can follow her @castro2355_mg, the Rogel Cancer Center @UMRogelCancer, the department of neurosurgery @umichneuro, Michigan Neurscience Institute @UM_MNI and the department of cell and developmental biology @UMCDB on X
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
Addiction is a lifelong disease and not a moral failing
On today’s The Fundamentals is Dr. Brummett, Professor at the University of Michigan where he serves as the Senior Associate Chair for Research in the Department of Anesthesiology. He has more than 280 publications, including articles in top journals such as JAMA, JAMA Surgery, Anesthesiology, and Annals of Surgery. He is the Co-Director of the Opioid Prescribing Engagement Network or OPEN at the University of Michigan, which aims to apply a preventative approach to the opioid epidemic in the US through appropriate prescribing after surgery, dentistry and emergency medicine. Moreover, he is the Co-Director of the cross-campus Opioid Research Institute, which was launched in the spring of 2023. He leads multiple NIH grants studying these concepts and receives funding from the Michigan Department of Health and Human Services, SAMHSA, CDC, and multiple foundations. You can learn more about Dr. Brummett here, and you can follow Dr. Brummett @drchadb and the department of anesthesiology @UMichAnesthesia on X.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
From Patients to Progress: Advancing Autoimmune Research
Today on The Fundamentals, our guest is Dr. Michelle Kahlenberg, an Associate Professor of Internal Medicine and Dermatology, the Giles Bole and Dorothy Mulkey Research Professor of Rheumatology and the Vice Chair for Basic and Translational Research in Internal Medicine. Her clinical work is centered on the care of patients with lupus, including those with refractory skin disease. In addition to running her lab, she's an active member of the Immunology Training Program and has received national recognition for her research.